ETON
Income statement / Annual
Last year (2023), Eton Pharmaceuticals, Inc.'s total revenue was $31.64 M,
an increase of 48.90% from the previous year.
In 2023, Eton Pharmaceuticals, Inc.'s net income was -$936,000.00.
See Eton Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$31.64 M
|
$21.25 M
|
$21.83 M
|
$39,000.00
|
$959,000.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$10.58 M |
$6.93 M |
$2.62 M |
$286,000.00 |
$453,000.00 |
$63,000.00 |
$13,000.00 |
| Gross Profit |
$21.06 M |
$14.32 M |
$19.21 M |
-$247,000.00 |
$506,000.00 |
-$63,000.00 |
-$13,000.00 |
| Gross Profit Ratio |
0.67 |
0.67 |
0.88 |
-6.33 |
0.53 |
0 |
0 |
| Research and Development
Expenses |
$3.32 M
|
$4.00 M
|
$6.24 M
|
$14.10 M
|
$11.56 M
|
$5.63 M
|
$3.93 M
|
| General & Administrative
Expenses |
$18.93 M
|
$18.58 M
|
$14.47 M
|
$12.76 M
|
$7.55 M
|
$4.69 M
|
$4.83 M
|
| Selling & Marketing
Expenses |
$67,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$1.62 M
|
| Selling, General &
Administrative Expenses |
$18.93 M
|
$18.58 M
|
$14.47 M
|
$12.76 M
|
$7.55 M
|
$4.69 M
|
$3.21 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$22.25 M |
$22.58 M |
$20.70 M |
$26.86 M |
$19.11 M |
$10.32 M |
$7.14 M |
| Cost And Expenses |
$32.83 M |
$29.51 M |
$23.33 M |
$27.15 M |
$19.56 M |
$10.32 M |
$7.15 M |
| Interest Income |
$0.00 |
$761,000.00 |
$1.01 M |
$859,000.00 |
$281,000.00 |
$164,000.00 |
$52,500.00 |
| Interest Expense |
$503,000.00 |
-$761,000.00 |
$1.01 M |
-$859,000.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$901,000.00
|
$1.77 M
|
$447,000.00
|
$651,000.00
|
$447,000.00
|
$63,000.00
|
$13,000.00
|
| EBITDA |
-$291,000.00
|
-$6.49 M
|
-$1.03 M
|
-$26.46 M
|
-$18.15 M
|
-$7.68 M
|
-$7.14 M
|
| EBITDA Ratio |
-0.01 |
-0.31 |
-0.05 |
-678.46 |
-18.93 |
0 |
0 |
| Operating Income Ratio
|
-0.04
|
-0.39
|
-0.07
|
-695.15
|
-19.4
|
0
|
0
|
| Total Other
Income/Expenses Net |
$503,000.00
|
-$761,000.00
|
-$460,000.00
|
-$859,000.00
|
$281,000.00
|
-$2.58 M
|
-$6,000.00
|
| Income Before Tax |
-$689,000.00 |
-$9.02 M |
-$1.96 M |
-$27.97 M |
-$18.32 M |
-$12.74 M |
-$7.16 M |
| Income Before Tax Ratio
|
-0.02
|
-0.42
|
-0.09
|
-717.18
|
-19.1
|
0
|
0
|
| Income Tax Expense |
$247,000.00 |
$761,000.00 |
$1.01 M |
$859,000.00 |
-$281,000.00 |
-$2.58 M |
$0.00 |
| Net Income |
-$936,000.00 |
-$9.78 M |
-$2.96 M |
-$28.83 M |
-$18.04 M |
-$12.74 M |
-$7.16 M |
| Net Income Ratio |
-0.03 |
-0.46 |
-0.14 |
-739.21 |
-18.81 |
0 |
0 |
| EPS |
-0.0365 |
-0.39 |
-0.12 |
-1.37 |
-1.02 |
-1.99 |
-0.41 |
| EPS Diluted |
-0.0365 |
-0.39 |
-0.12 |
-1.37 |
-1.02 |
-1.99 |
-0.41 |
| Weighted Average Shares
Out |
$25.65 M
|
$25.15 M
|
$25.21 M
|
$21.01 M
|
$17.76 M
|
$6.42 M
|
$17.46 M
|
| Weighted Average Shares
Out Diluted |
$25.65 M
|
$25.15 M
|
$25.21 M
|
$21.01 M
|
$17.76 M
|
$6.42 M
|
$17.46 M
|
| Link |
|
|
|
|
|
|
|
